PMID- 29808485
STAT- In-Data-Review
LR  - 20180625
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 48
IP  - 2
DP  - 2018 Jul
TI  - Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in
      individuals with primary sclerosing cholangitis and inflammatory bowel disease.
PG  - 190-195
LID - 10.1111/apt.14829 [doi]
AB  - BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic, progressive
      cholestatic biliary disease associated with inflammatory bowel disease (IBD) with
      no known cure. AIM: To evaluate the effect of biological therapies on PSC
      progression in IBD patients. METHODS: We performed a retrospective cohort study
      of 88 cases (75 unique patients with 12 patients treated >1 biologics) of IBD (48
      ulcerative colitis, 24 Crohn's disease and 3 indeterminate colitis) with
      concomitant PSC who received biological therapy (42 infliximab, 19 adalimumab, 27
      vedolizumab) between June 2002 and October 2017. Hepatic biochemistries were
      compared using the paired t-test (patients served as their own controls) </=3
      months before and 6-8 and 12-14 months after biological initiation. Radiographic 
      information of biliary stenosis and liver fibrosis were obtained via abdominal
      ultrasound, abdominal magnetic resonance imaging and magnetic resonance
      elastography. RESULTS: Use of adalimumab was associated with a significant
      decrease in alkaline phosphatase (ALP) after 6-8 months (P = 0.03; mean change
      -70 U/L, standard deviation [SD] 88 U/L) compared to vedolizumab (mean change +50
      U/L, SD 142 U/L) or infliximab (mean change +37 U/L, SD 183 U/L) but the change
      was not significant after 12-14 months (P = 0.24). No significant decreases were 
      observed with AST, ALT, total or direct bilirubin, elastography score or
      radiographic imaging of biliary tree dilation/strictures with any biological
      therapy after 6-8 or 12-14 months. CONCLUSIONS: Current evidence suggests that
      biological therapies used for the treatment of IBD are not effective treatments
      for PSC. Further study is needed to elucidate any potential beneficial effect of 
      adalimumab on PSC.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Tse, C S
AU  - Tse CS
AD  - Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Loftus, E V Jr
AU  - Loftus EV Jr
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
FAU - Raffals, L E
AU  - Raffals LE
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
FAU - Gossard, A A
AU  - Gossard AA
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
FAU - Lightner, A L
AU  - Lightner AL
AD  - Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
LA  - eng
PT  - Journal Article
DEP - 20180528
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
EDAT- 2018/05/29 06:00
MHDA- 2018/05/29 06:00
CRDT- 2018/05/30 06:00
PHST- 2018/03/09 00:00 [received]
PHST- 2018/03/28 00:00 [revised]
PHST- 2018/05/08 00:00 [accepted]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2018/05/29 06:00 [medline]
PHST- 2018/05/30 06:00 [entrez]
AID - 10.1111/apt.14829 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2018 Jul;48(2):190-195. doi: 10.1111/apt.14829. Epub 2018
      May 28.